Atlas Trials

Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant

Clinical trial NCT06197672 · RECRUITING

Trial details

NCT number
NCT06197672
Sponsor
Huda Salman
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Acute Myeloid Leukemia
Start date
2024-03-19
Primary completion
2027-12-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.